Chapin Davis, Inc. Lineage Cell Therapeutics, Inc. Transaction History
Chapin Davis, Inc.
- $293 Billion
- Q1 2025
A detailed history of Chapin Davis, Inc. transactions in Lineage Cell Therapeutics, Inc. stock. As of the latest transaction made, Chapin Davis, Inc. holds 20,029 shares of LCTX stock, worth $9,213. This represents 0.0% of its overall portfolio holdings.
Number of Shares
20,029Holding current value
$9,213% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding LCTX
# of Institutions
140Shares Held
107MCall Options Held
22.1KPut Options Held
0-
Broadwood Capital Inc New York, NY41.7MShares$19.2 Million1.65% of portfolio
-
Black Rock Inc. New York, NY9.56MShares$4.4 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA8.63MShares$3.97 Million0.0% of portfolio
-
Perceptive Advisors LLC New York, NY7.24MShares$3.33 Million0.12% of portfolio
-
Defender Capital, Llc.6.31MShares$2.9 Million1.19% of portfolio
About Lineage Cell Therapeutics, Inc.
- Ticker LCTX
- Exchange NYSE
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 169,755,008
- Market Cap $78.1M
- Description
- Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapies for the treatment of degenerative diseases in the United States and internationally. The company develops OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa clinical trial for the treatment of the dry age-re...